Short answer
CAPRICOR THERAPEUTICS, INC. (CAPR) filed an 8-K current report with the SEC on March 10, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). FDA lifted prior Complete Response Letter (CRL) and resumed BLA review for Deramiocel in Duchenne muscular dystrophy cardiomyopathy: major regulatory hurdle cleared.
CAPRICOR THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA lifted prior Complete Response Letter (CRL) and resumed BLA review for Deramiocel in Duchenne muscular dystrophy cardiomyopathy: major regulatory hurdle cleared
- CRL removal signals FDA's prior objections addressed, meaningfully raising probability of full approval
- Deramiocel targets DMD cardiomyopathy, a rare/orphan indication with no approved cell therapies: significant market opportunity if approved
Item 8.01 · Other Events
- FDA lifted CRL and resumed BLA review for Deramiocel (cell therapy for DMD cardiomyopathy): major regulatory reversal removing a key overhang
- Classified as Class 2 resubmission with PDUFA action date of August 22, 2026: sets clear approval timeline for investors
- Company flagged potential eligibility for a Priority Review Voucher (PRV): PRVs have sold for $100M+ historically, representing significant non-dilutive upside
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CAPRICOR THERAPEUTICS, INC. 8-K filings
Get the next CAPR 8-K as it lands
Follow CAPR for push alerts, or ask the research agent what this filing means.